Candy giant Mars partners with biotech firm to gene-edit cocoa supply
Investment
CNBC

Candy giant Mars partners with biotech firm to gene-edit cocoa supply

August 6, 2025
06:03 PM
2 min read
AI Enhanced
investmenteconomystocksconsumer goodsbiotechnologymarket cyclesseasonal analysisregulatory

Key Takeaways

The goal is to create cacao plants that can better withstand disease, heat and other climate-related stresses that can put global chocolate supply at risk.

Article Overview

Quick insights and key information

Reading Time

2 min read

Estimated completion

Category

investment

Article classification

Published

August 6, 2025

06:03 PM

Source

CNBC

Original publisher

Key Topics
investmenteconomystocksconsumer goodsbiotechnologymarket cyclesseasonal analysisregulatory

In this articleCRSP.AD.IXIC your favorite stocksCREATE FREE ACCOUNTPackages of M&M's milk chocolate candy are stacked at a Costco Wholesale store in San Diego, California, on July 12, 2025.Kevin Carter | Getty Images News | Getty ImagesCandy maker Mars said Wednesday it has partnered with bio company Pairwise to speed up the development of more resilient cocoa using CRISPR-based gene editing nology.The agreement gives the M&M's maker access to Pairwise's Fulcrum platform, which includes a library of plant traits, and gives Mars the ability to tailor its crops to be stronger and more sustainable.CRISPR is a gene-editing tool that makes fast and precise changes to DNA

In farming, it's used to imve crops by targeting different traits such as drought and disease resistance.The goal is to create cacao plants — the source of cacao beans, which are then roasted and made into cocoa — that can better withstand disease, heat and other climate-related stresses that can put global chocolate supply at risk.In October, Starbucks invested in two innovation farms in Central America to tect the chain's coffee supply from global warming

The farms develop climate-resilient coffee and test nologies such as drones and mechanization.Gene editing allows for faster and more precise trait development than traditional breeding, Pairwise said in a press release.CRISPR has garnered attention in recent years for its applications in health care

In late 2023, the U.S

Food and Drug Administration apved the first gene-editing treatment for sickle cell disease."At Mars, we believe CRISPR has the potential to imve crops in ways that support and strengthen global supply chains," said Carl Jones, Plant Sciences Director at Mars, in the release.Last month, the candy giant announced a $2 billion investment in U.S. manufacturing through 2026

This includes a new $240 million investment for a Nature's Bakery facility in Utah.Don’t miss these insights from CNBC Bank of America says these five stocks have more room to run ahead of earningsThese overbought stocks could take a dip after the market's record gainsGoldman Sachs is getting worried the economyWhat the prediction are saying the big Wall Street events ahead